Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer, announced its participation in five virtual investor conferences. These include Cowen's IO Next Summit on November 15, Stifel's Healthcare Conference on November 16, and others through December 6. Webcasts will be available on Allogene's website, providing investors with insights into the company's innovative therapies and future developments.

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences.

Cowen's 5th Annual IO Next Summit
Monday, November 15, 2021
8:45 AM PT/11:45 AM ET

Stifel 2021 Virtual Healthcare Conference
Tuesday, November 16, 2021
11:00 AM PT/2:00 PM ET

Jefferies London Healthcare Conference
Thursday, November 18, 2021
Pre-recorded session available starting at 1:00 AM PT/8:00 AM GMT

Evercore ISI 4th Annual HealthCONx Conference
Tuesday, November 30, 2021
12:30 PM PT/3:30 PM ET

The JMP Securities Hematology and Oncology Summit
Monday, December 6, 2021
12:00 PM PT/3:00 PM ET

Webcasts will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

FAQ

What are the dates of the upcoming investor conferences for Allogene (ALLO)?

Allogene is participating in five upcoming conferences: Cowen's IO Next Summit on November 15, Stifel's Healthcare Conference on November 16, Jefferies London Healthcare Conference on November 18, Evercore ISI's HealthCONx Conference on November 30, and JMP Securities' Hematology and Oncology Summit on December 6.

Where can I find the webcasts for Allogene's investor conferences?

Webcasts for Allogene's investor conferences will be accessible on their website under the Investors tab in the News and Events section.

What is the focus of Allogene Therapeutics (ALLO)?

Allogene Therapeutics is focused on pioneering the development of allogeneic CAR T therapies aimed at treating cancer with 'off-the-shelf' cell therapy solutions.

How is Allogene Therapeutics (ALLO) planning to deliver its CAR T therapies?

Allogene aims to deliver CAR T therapies on-demand, more reliably, and at greater scale to increase patient accessibility.

What is AlloCAR T™, and why is it significant?

AlloCAR T™ is a trademarked cell therapy platform developed by Allogene Therapeutics, significant for its potential to provide readily available CAR T therapies to cancer patients.